207 related articles for article (PubMed ID: 32417350)
1. Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy.
Zschaeck S; Löck S; Hofheinz F; Zips D; Saksø Mortensen L; Zöphel K; Troost EGC; Boeke S; Saksø M; Mönnich D; Seidlitz A; Johansen J; Skripcak T; Gregoire V; Overgaard J; Baumann M; Krause M
Radiother Oncol; 2020 Aug; 149():189-196. PubMed ID: 32417350
[TBL] [Abstract][Full Text] [Related]
2. Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging.
Löck S; Perrin R; Seidlitz A; Bandurska-Luque A; Zschaeck S; Zöphel K; Krause M; Steinbach J; Kotzerke J; Zips D; Troost EGC; Baumann M
Radiother Oncol; 2017 Sep; 124(3):533-540. PubMed ID: 28843726
[TBL] [Abstract][Full Text] [Related]
3. Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
Löck S; Linge A; Seidlitz A; Bandurska-Luque A; Nowak A; Gudziol V; Buchholz F; Aust DE; Baretton GB; Zöphel K; Steinbach J; Kotzerke J; Overgaard J; Zips D; Krause M; Baumann M; Troost EGC
Radiother Oncol; 2019 Jun; 135():43-50. PubMed ID: 31015169
[TBL] [Abstract][Full Text] [Related]
4. PET measured hypoxia and MRI parameters in re-irradiated head and neck squamous cell carcinomas: findings of a prospective pilot study.
Rogasch J; Beck M; Stromberger C; Hofheinz F; Ghadjar P; Wust P; Budach V; Amthauer H; Tinhofer I; Furth C; Walter-Rittel TC; Zschaeck S
F1000Res; 2020; 9():1350. PubMed ID: 33796277
[No Abstract] [Full Text] [Related]
5. FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients.
Bandurska-Luque A; Löck S; Haase R; Richter C; Zöphel K; Abolmaali N; Seidlitz A; Appold S; Krause M; Steinbach J; Kotzerke J; Zips D; Baumann M; Troost EGC
Radiother Oncol; 2019 Jan; 130():97-103. PubMed ID: 30293643
[TBL] [Abstract][Full Text] [Related]
6. A prospective clinical study of ¹⁸F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy.
Servagi-Vernat S; Differding S; Hanin FX; Labar D; Bol A; Lee JA; Grégoire V
Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1544-52. PubMed ID: 24570097
[TBL] [Abstract][Full Text] [Related]
7. The utility of multiparametric MRI to characterize hypoxic tumor subvolumes in comparison to FMISO PET/CT. Consequences for diagnosis and chemoradiation treatment planning in head and neck cancer.
Wiedenmann N; Grosu AL; Büchert M; Rischke HC; Ruf J; Bielak L; Majerus L; Rühle A; Bamberg F; Baltas D; Hennig J; Mix M; Bock M; Nicolay NH
Radiother Oncol; 2020 Sep; 150():128-135. PubMed ID: 32544609
[TBL] [Abstract][Full Text] [Related]
8. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH
Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199
[TBL] [Abstract][Full Text] [Related]
9. Prospective Evaluation of a Tumor Control Probability Model Based on Dynamic
Thorwarth D; Welz S; Mönnich D; Pfannenberg C; Nikolaou K; Reimold M; La Fougère C; Reischl G; Mauz PS; Paulsen F; Alber M; Belka C; Zips D
J Nucl Med; 2019 Dec; 60(12):1698-1704. PubMed ID: 31076504
[TBL] [Abstract][Full Text] [Related]
10. Influence of FAZA PET hypoxia and HPV-status for the outcome of head and neck squamous cell carcinoma (HNSCC) treated with radiotherapy: Long-term results from the DAHANCA 24 trial (NCT01017224).
Saksø M; Mortensen LS; Primdahl H; Johansen J; Kallehauge J; Hansen CR; Overgaard J
Radiother Oncol; 2020 Oct; 151():126-133. PubMed ID: 32805273
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of tumor hypoxia assessed by 18F-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: possible implications for radiotherapy treatment planning strategies.
Bollineni VR; Koole MJ; Pruim J; Brouwer CL; Wiegman EM; Groen HJ; Vlasman R; Halmos GB; Oosting SF; Langendijk JA; Widder J; Steenbakkers RJ
Radiother Oncol; 2014 Nov; 113(2):198-203. PubMed ID: 25434768
[TBL] [Abstract][Full Text] [Related]
12. Kinetic Evaluation of the Hypoxia Radiotracers [
Choen S; Kent MS; Chaudhari AJ; Cherry SR; Krtolica A; Zwingenberger AL
Nucl Med Mol Imaging; 2023 Feb; 57(1):16-25. PubMed ID: 36643946
[TBL] [Abstract][Full Text] [Related]
13. Overlap of highly FDG-avid and FMISO hypoxic tumor subvolumes in patients with head and neck cancer.
Mönnich D; Thorwarth D; Leibfarth S; Pfannenberg C; Reischl G; Mauz PS; Nikolaou K; la Fougère C; Zips D; Welz S
Acta Oncol; 2017 Nov; 56(11):1577-1582. PubMed ID: 28849721
[TBL] [Abstract][Full Text] [Related]
14. Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.
Wiedenmann N; Bunea H; Rischke HC; Bunea A; Majerus L; Bielak L; Protopopov A; Ludwig U; Büchert M; Stoykow C; Nicolay NH; Weber WA; Mix M; Meyer PT; Hennig J; Bock M; Grosu AL
Radiat Oncol; 2018 Aug; 13(1):159. PubMed ID: 30157883
[TBL] [Abstract][Full Text] [Related]
15. Generation of biological hypotheses by functional imaging links tumor hypoxia to radiation induced tissue inflammation/glucose uptake in head and neck cancer.
Zschaeck S; Zöphel K; Seidlitz A; Zips D; Kotzerke J; Baumann M; Troost EGC; Löck S; Krause M
Radiother Oncol; 2021 Feb; 155():204-211. PubMed ID: 33252044
[TBL] [Abstract][Full Text] [Related]
16. Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy.
Lee N; Nehmeh S; Schöder H; Fury M; Chan K; Ling CC; Humm J
Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):101-8. PubMed ID: 19203843
[TBL] [Abstract][Full Text] [Related]
17. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
[TBL] [Abstract][Full Text] [Related]
18. Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure.
Zschaeck S; Haase R; Abolmaali N; Perrin R; Stützer K; Appold S; Steinbach J; Kotzerke J; Zips D; Richter C; Gudziol V; Krause M; Zöphel K; Baumann M
Acta Oncol; 2015; 54(9):1355-63. PubMed ID: 26398663
[TBL] [Abstract][Full Text] [Related]
19. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial.
Mortensen LS; Johansen J; Kallehauge J; Primdahl H; Busk M; Lassen P; Alsner J; Sørensen BS; Toustrup K; Jakobsen S; Petersen J; Petersen H; Theil J; Nordsmark M; Overgaard J
Radiother Oncol; 2012 Oct; 105(1):14-20. PubMed ID: 23083497
[TBL] [Abstract][Full Text] [Related]
20. Head and neck tumor hypoxia imaging by 18F-fluoroazomycin-arabinoside (18F-FAZA)-PET: a review.
Halmos GB; Bruine de Bruin L; Langendijk JA; van der Laan BF; Pruim J; Steenbakkers RJ
Clin Nucl Med; 2014 Jan; 39(1):44-8. PubMed ID: 24152663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]